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The development and application of diverse BAC transgenic rodent lines has enabled
rapid progress for precise molecular targeting of genetically-defined cell types in the
mammalian central nervous system. These transgenic tools have played a central role
in the optogenetic revolution in neuroscience. Indeed, an overwhelming proportion of
studies in this field have made use of BAC transgenic Cre driver lines to achieve targeted
expression of optogenetic probes in the brain. In addition, several BAC transgenic mouse
lines have been established for direct cell-type specific expression of Channelrhodopsin-2
(ChR2). While the benefits of these new tools largely outweigh any accompanying
challenges, many available BAC transgenic lines may suffer from confounds due in part
to increased gene dosage of one or more “extra” genes contained within the large BAC
DNA sequences. Here we discuss this under-appreciated issue and propose strategies for
developing the next generation of BAC transgenic lines that are devoid of extra genes.
Furthermore, we provide evidence that these strategies are simple, reproducible, and
do not disrupt the intended cell-type specific transgene expression patterns for several
distinct BAC clones. These strategies may be widely implemented for improved BAC
transgenesis across diverse disciplines.
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INTRODUCTION
Bacterial Artificial Chromosomes (BACs) are large DNA con-
structs composed of a small cloning vector backbone ligated
to large fragments of restriction-digested genomic DNA that
can be stably propagated as well as manipulated in bacterial
host cells. Extensive BAC libraries have been constructed with
genomic material from a variety of organisms and have served
as indispensable tools for large-scale genome sequencing and
mapping efforts. One such project culminated in the release of
three landmark mouse BAC libraries derived from the C57BL/6J
and 129S6/SvEvTac strains with a combined 30-fold coverage of
the mouse genome (Osoegawa et al., 2000). This resource was
quickly tapped to create the first BAC transgenic mouse line
with functional transgene expression driven by successful integra-
tion of an engineered Bacterial Artificial Chromosome into the
mouse genome (Yang et al., 1997). This pioneering work estab-
lished the feasibility of diverse targeted manipulations of BAC
clones in E. coli by homologous recombination, a method now
commonly referred to as BAC recombineering (recombination-
mediated genetic engineering). Furthermore, this work boldly
asserted the incredible potential of BACs for gene therapy, dis-
ease modeling, and other basic research applications aimed at
deciphering gene function.
The ability to obtain andmanipulate BAC clones with genomic
DNA spanning hundreds of kilobases is highly advantageous for
transgenic applications given that most mouse BAC clones (aver-
age insert size 150–200 kb) encompass one or more genes includ-
ing flanking regions essential to instructing cell-type specific
expression patterns in vivo. Furthermore, the presence of large
spans of insulating genetic material around a transgene expres-
sion cassette can curb transgene silencing or mosaic expression
in vivo due to position effect variegation following random inte-
gration into unfavorable sites of the host genome (Bian and
Belmont, 2010). Indeed, Yang et al. (1997) proposed that BAC
transgenesis would be especially expedient for creating mice with
faithful cell-type specific expression of Cre recombinase for gene
disruption in mice, an idea that directly catalyzed the immensely
successful Gene Expression and Nervous System ATlas (GENSAT)
project at Rockefeller University led by Nathaniel Heintz and
colleagues (Gong et al., 2003; Heintz, 2004). Importantly, BAC
transgenic Cre driver rodents (particularly the extensive col-
lection from the GENSAT project) have played a pivotal role
in expanding the utility of emerging optogenetics-based tech-
nologies in neuroscience by enabling unprecedented access to
monitor and manipulate genetically-defined cell populations in
the nervous systemwhen used in combination with Cre-inducible
expression strategies for diverse optogenetic probes (Atasoy et al.,
2008; Cardin et al., 2009; Petreanu et al., 2009; Witten et al., 2011;
Madisen et al., 2012; Saunders et al., 2012; Zariwala et al., 2012).
In addition, numerous laboratories have tapped into the knowl-
edge base of the GENSAT project to guide the development of
new tools such as the first collections of BAC transgenic mice with
direct cell-type specific expression of ChR2 in the central nervous
system (Hagglund et al., 2010; Zhao et al., 2011). Collectively,
these BAC transgenic tools are now widely implemented for opto-
genetic deconstruction of complex neural circuits that mediate
diverse animal behaviors and brain states (Tsai et al., 2009; Kravitz
et al., 2010; Witten et al., 2010; Aponte et al., 2011; Halassa et al.,
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2011; Yizhar et al., 2011; Tai et al., 2012; Tan et al., 2012; Bock
et al., 2013; Chaudhury et al., 2013; Cui et al., 2013; Stamatakis
et al., 2013; Steinberg et al., 2013). The broader topic of opto-
genetic dissection of behavior in mammalian model systems has
been extensively reviewed elsewhere (Tye and Deisseroth, 2012;
Yizhar, 2012; Lenz and Lobo, 2013; Nieh et al., 2013).
Here we propose strategies for developing the next generation
of BAC transgenic lines that are devoid of overexpressed extra
genes. We describe multiple BAC recombineering strategies for
eliminating undesirable extra genes from BAC clones in order to
circumvent confounds due to overexpression of such extra genes
in BAC transgenic lines. In addition, we demonstrate that these
modification procedures may be performed in parallel or sequen-
tially with routine BAC recombineering steps for introducing a
transgene of interest under the control of cell-type specific pro-
moter elements. Together, these procedures effectively result in
pure transgenic expression cassettes ≥65 kb in size that can be
used in pronuclear injection to produce BAC transgenic animals.
These steps are simple, efficient, reproducible, and can be imple-
mented for the modification of any BAC clone. We are applying
these methods in developing the next generation of BAC trans-
genic animals for optogenetics-based research and expect these
strategies may be widely adapted across diverse disciplines.
MATERIALS AND METHODS
TARGETING VECTOR CONSTRUCTION
A pBlueScript-derived vector iTV1 was used to generate BAC tar-
geting vectors. iTV1 contains cloning sites for A and B homology
arms which flank a large multiple cloning site, bovine growth
hormone polyadenylation (BGHpA) signal, and FRT flanked
neomycin resistance cassette (FRT-NEO-FRT). First, iTV1 was
modified by addition of the woodchuck post-translational reg-
ulatory element (WPRE) upstream of the BGHpA to create
iTV1-WPRE. This modification was chosen to improve trans-
gene protein expression level and RNA stability. BAC specific
homology arms A and B (400–600 bp each arm) were PCR
amplified from BAC template DNA and cloned into iTV1-
WPRE. In a separate mammalian expression vector, two copies of
ChR2(E123T/H134R), herein referred to simply as ChETATR, and
the orange/red emitting tdTomato fluorophore were combined
using viral 2A linkers. We selected P2A with a C-terminal GSG
linker because this combination was shown to be the most effi-
ciently processed of all viral 2A elements (Kim et al., 2011) and
thus was the most likely to enable a complete physical uncoupling
of the opsin and fluorophore with no significant unprocessed pro-
tein fraction. The ChETATR-P2A-ChETATR-P2A-tdTomato cas-
sette (i.e., 2xChETA-P2A-tdTomato) was then sub-cloned into the
large multiple cloning site of iTV1-A/B-WPRE to complete the
BAC targeting vectors. In this final cloning step great care was
taken to ensure minimal disruptions to the junction between the
A Box and the start of the ChETA sequence, except for addition of
a Kozak consensus sequence.
BAC TRIMMING CASSETTES
The pBlueScript-based deletion cassettes were constructed by
standard PCR and cloning methods. The order of assembled fea-
tures is as follows: (1) a 50–350 bp BAC-specific homology arm
(selected to target the preferred location for BAC trimming in a
BAC clone of interest), (2) AscI and NotI restriction sites (for later
removal of the BAC vector during purification of BAC DNA for
pronuclear injection), (3) the bla gene encoding ampicillin resis-
tance (AmpR), and (4) a “loxP deletion” homology arm (targeting
the BAC vector sequence adjacent to the wild-type loxP site in
pBACe3.6 or pTARBAC1 vectors).
loxP deletion arm: 5′-gttaacgtgccggcacggcctgggtaaccaggtattttgtc
cacataaccgtgcgcaaaatgttgtggataagcaggacacagcagcaatccacagcaggcat
acaaccgcacaccgaggttactccgttctacaggttacgacgacatgtcaatacttgcccttgac
aggcattgatggaatcgtagtctcacgctgatagtctgatcgacaatacaagtg-3′
BAC clone specific deletion arms:
Adora2a BAC (RP24-238K3): 5′-gagctgagtggccagcgacctattgcc
taggcatagataaccatatatca-3′
Drd2 BAC (RP23-161H15): 5′-gagaccagtgccagcagaagctatggtc
attgtggtgataggagcgtggctga-3′
Chat BAC (RP24-256F2): 5′-ttcagtccactatactttcctgcttttcttcatg
gcttagcaaggttcctggacctcagcagagttaatagaaaatgcaggctgcaactggatggtt
agcgatgaaactaagcaactctagacagtgcagtcagacacatactttctctaactggcggga
gttactcactcacgcaatcacctctaacacttaaccacagcaggtggaaattgagttagtttaa
gaggctaactctgtgctaagcctggggacttgggacaggaaagccttggccccgcccagcag
tggccccgcccacctctctgaaggctggactggcggttgcctagcagcagg-3′
DAT BAC (RP24-269I17): 5′-agatataacctacctttgcatgttagccagga
ttaagatttatattaccg-3′
Pvalb BAC (RP24-306A6): 5′-ttccggaaggtgcacagcacgggtgctgtc
cgcagttgtttgctgtgcaagcatgcagggccttcctgtcttcctcactgctcaacgttgcacat
ttttccctccccgctatttcagtttttagggttcataacatgcttgggctttaaagatggcatttcg
attctggacgtgaa-3′
Vgat BAC (RP24-246L1): 5′-agttccatccctggaacctattgggtgaagag
aacaggcatcttggcacgctcccacacccatcacgcaataaataaacaaatgaacagaaaaa
gaagtcaaaggggaaggagattagcttaacacggtcacaaaactaagggctagatctgcaag
gctatgcagacagagaccaagggagagtaaggggacagggaggggcggagtccagcccag
tgtgggtggagcctttggtcccttagttagagca-3′
GENE INACTIVATION CASSETTES
Sfxn1 homology arms A and B (1 kb each) were PCR ampli-
fied and cloned into pBlueScript II. A 29 bp dsOligo containing
a three-frame translational stop mutation and diagnostic SalI
restriction site (5′-gaattctagataactaggtcgacctgcag-3′), was synthe-
sized and cloned between the two homology arms. This vector is
designed to insert the three-frame translational stop cassette after
the 13th codon in the Sfxn1 coding region in the Drd1a-spanning
BAC clone RP23-47M2 and was thus called “Sfxn1 Target.” A
second vector “VAChT Target” was designed with the identical
strategy except that homology arms A and B directed the inser-
tion of the three-frame translational stop cassette after the 5th
codon in the Slc18a3 coding region (VAChT locus) in the Chat-
spanning BAC clone RP24-256F2. Relatively long 1 kb homology
arms were selected in order to ensure a high efficiency of homolo-
gous recombination since this targeting cassette does not contain
a selectionmarker for screening andmust be used in combination
with a separate iTV1-based targeting vector.
Critical regions of all constructs were verified by DNA
sequencing. The targeting vectors were linearized by restriction
digestion and purified in preparation for subsequent use in BAC
recombineering steps. Care was taken to ensure adequate dura-
tion of restriction digestion (or in some cases two sequential
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rounds of digestions were performed) such that there was no
contaminating uncut plasmid carried over into the electropora-
tion step.
Additional information including complete DNA sequences of
the targeting vectors and modified BAC clones used in this study
are available upon request.
BAC RECOMBINEERING
Appropriate BAC clones were selected from the RP23/RP24 C57
mouse BAC library following a detailed analysis using the Esembl
Genome Browser (www.Ensembl.org) and were obtained from
the Children’s Hospital Oakland Research Institute (CHORI). The
intact BAC DNA was isolated from the original host DH10B
strain by BAC mini-prep and verified by restriction digestion and
pulsed field gel electrophoresis (PFGE). Successfully verified BAC
DNA was transferred into the EL250 strain in preparation for
recombineering steps and maintained as glycerol stocks stored
at −80◦C.
Most often the first strategic recombineering step was BAC
trimming to delete unwanted regions of BAC DNA harboring
extra genes. 20mL of LB media plus chloramphenicol were inoc-
ulated with EL250 cells containing the target BAC clone and
placed in a shaking incubator at 32◦C for 2 h until the cells
reached an early log growth phase. The culture was induced for
15min at 42◦C in a shaking water bath to permit transient expres-
sion of genes required for homologous recombination. Cells were
rapidly chilled, pelleted, and washed three times with ice-cold
MilliQ water to remove salts. Approximately 10–100 ng of lin-
earized BAC trimming vector was added to 50µL of induced cells
in a 1mm gap cuvette and the mixture was immediately elec-
troporated (1.75 kV, 25µF, 200Ohms). The cells were recovered
and plated onto LB plus chloramphenicol and carbenicillin to
select for successful homologous recombination events, meaning
insertion of the AmpR cassette in place of the targeted region.
Double resistant clones were picked for further analysis to verify
the deletions.
In a second round of targeting the virtually identical steps
were performed to insert the ChETATR transgene expression cas-
sette at the initiating methionine start codon of the targeted gene
within the selected BAC clone by homologous recombination. In
this case, successfully modified clones were resistant to chloram-
phenicol, carbenicillin, and kanamycin due to insertion of the
FRT-NEO-FRT in the targeting vector. (Note: although it is eas-
ily feasible to perform the first and second targeting events in
a single step due to the insertion of two different selection cas-
settes, it was preferable to do these steps in series in order to save
a glycerol stock of the successfully trimmed BAC in EL250 cells
for future reuse). The NEO cassette was then excised from the
modified BAC by arabinose induction of flp recombinase in the
EL250 cells. Modified BAC clones were extensively screened for
accuracy and the correctly targeted BAC DNA was grown in large
scale and purified using the BAC100 kit (Clontech). 10–15µg of
BAC DNA was restriction digested with NotI or AscI to liberate
the BAC vector from insert and the linear fragments were sepa-
rated by PFGE. The intact BAC insert band was excised from the
PFG, electroeluted, and spot dialyzed against fresh microinjection
buffer.
For gene inactivation recombineering experiments the lin-
earized Sfxn1 Target DNA was combined at ∼20-fold molar
excess with linearized iTV1-D1-ChETA targeting construct DNA
immediately prior to the electroporation step. This was best
accomplished by diluting linearized iTV1-D1-ChETA targeting
DNA 1:20 in water and then adding approximately equal volumes
of linearized Sfxn1 Target and diluted iTV1-D1-ChETA into the
cuvette for the electroporation into induced EL250 cells propagat-
ing the Drd1a-spanning BAC RP23-47M2. Double recombinants
were identified by resistance to chloramphenicol and kanamycin
and further verified by PCR screening and subsequent restriction
digestion and PFGE of isolated BAC DNA to test for the incorpo-
ration of the diagnostic SalI site. Large scale BAC DNA isolation
and processing for pronuclear injection were carried out as indi-
cated above. In additional experiments we used VAChT Target to
inactivate Slc18a3 in the Chat-spanning BAC RP24-256F2. This
dual targeting step was carried out together with the iTV1-Chat-
ChETA targeting vector following identical methods as for Sfxn1
inactivation.
PRONUCLEAR INJECTION AND IDENTIFICATION OF TRANSGENIC
FOUNDERS
Transgenic mice (pure C57BL/6 Taconic) were generated by
pronuclear injection of the highly purified intact BAC DNA into
fertilized oocytes at a concentration of 0.5–2.0 ng/µL. Genotypes
were determined by PCR frommouse tail DNA samples and line-
specific primer sets. Mice that had the transgene integrated in
the genome were kept as founders to establish distinct lines by
mating to C57BL/6J mice. One line each of Slc6a3-2xChETATR-
P2A-tdTomato (DAT-ChETA), Drd1a-2xChETATR-P2A-tdTomato
(D1-ChETA), and Adora2a-2xChETATR-P2A-tdTomato (A2A-
ChETA) were established for further analysis. Only hemizygous
mice on a pure C57 background were used for experiments in
this study. All research involving mice was conducted according
to the Institutional Animal Care and Use Committee guidelines
at MIT. All procedures were approved by the Institutional Animal
Care and Use Committee at MIT.
SLICE IMMUNOSTAINING AND CONFOCAL IMAGING
Mice were anesthetized with tribromoethanol (Avertin) and
transcardially perfused with phosphate buffered saline (137mM
NaCl, 10mM NaH2PO4, and 2.7mM KCl, pH = 7.4; PBS)
followed by 10% neutral-buffered formalin (Sigma-Aldrich, St
Louis, MO). Brains were post-fixed in 10% formalin at 4◦C
overnight. Fixed brains were sectioned (50µm) on a vibratome
(Leica Microsystems, Buffalo Grove, IL) and the free-floating sec-
tions were washed for 10min three times with PBS. Sections
were then blocked for 1 h at room temperature in PBS con-
taining 5% normal goat serum, 2% bovine serum albumin and
0.2% Triton-X 100. After blocking, the sections were incubated
overnight at 4◦C in blocking buffer containing one or more of
the following antibodies: anti-ChAT (1:200 dilution; Millipore
AB144P), anti-2A (1:500 dilution; Millipore ABS31), anti-red
fluorescent protein (1:500 dilution; Rockland 600-401-379), anti-
GFP (1:5000 dilution; Abcam AB6566), anti-DAT (1:300 dilu-
tion; Millipore MAB369), or anti-DARPP-32 (1:2000 dilution;
BD Transduction 611520). Following the overnight incubation,
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sections were washed for 20min three times with PBS and then
incubated for 1 h at room temperature in Alexa dye-conjugated
secondary antibody (1:1500; Invitrogen,Grand Island, NY). Alexa
dyes utilized were: Alexa Fluor 488 (A-10667, goat anti-mouse
and A-11034, goat anti-rabbit), and Alexa Fluor 555 (A-21429,
goat anti-rabbit). Sections were washed for 20min three times
with PBS, dried on a glass microscope slide and mounted
with VectaShield (Vector Laboratories, Burlingame, CA). Slides
were stored at −20◦C and were thawed to room temperature
immediately prior to imaging. Whole brain montage images
were acquired with CellSens software on an Olympus BX61
equipped with a motorized stage and epifluorescence illumina-
tion. Confocal z-stack images were acquired on an Olympus
Fluoview 1000 laser scanning confocal microscope equipped with
488 and 543 nm laser lines.
RESULTS
IMPLEMENTING WELL CHARACTERIZED BAC CLONES TO ACHIEVE
REPRODUCIBLE CELL-TYPE SPECIFIC TRANSGENE EXPRESSION
We have previously developed several BAC transgenic mouse lines
for expression of ChR2 in diverse neuronal subsets of the ner-
vous system (Zhao et al., 2011). Our general strategy has been
to select BAC clones that have previously been validated in the
GENSAT project, as determined by the successful development
of mouse lines for cell type-specific expression of Cre or EGFP.
With this strategy we have observed that independent BAC trans-
genic mouse lines created by modification of the same original
BAC clone exhibit highly reproducible cell-type specific trans-
gene expression that recapitulates endogenous gene expression
patterns. This is exemplified in the case of theChat-spanning BAC
clone RP23-246B12, which was successfully used to express both
EGFP and ChR2-EYFP in cholinergic neurons of the nervous
system (Figure 1). Thus, a known BAC clone can be modified
for expression of virtually any transgene of interest in a well-
defined neuronal subset with a relatively high probability of
success following pronuclear injection.
MOST BAC CLONES USED TO MAKE BAC TRANSGENIC LINES SPAN
MULTIPLE GENES
In the course of this work it was noted that the majority of BAC
clones selected for making BAC transgenic mice and rats con-
tained multiple extra genes in addition to the explicitly targeted
region (Table 1). Presumably this relates to the conventional wis-
dom that larger BAC clones spanning the targeted region aremore
likely to encompass the necessary regulatory elements for recapit-
ulating the desired transgene expression pattern. Thus, in order
to more broadly assess this issue of increased gene dosage for
off-target genes we analyzed the entire collection of BAC clones
from the GENSAT Cre driver mouse repository (http://www.
gensat.org/cre.jsp). In total, 139 BAC clones from the RP23/RP24
C57 library were located and viewed with alignment to the
mouse genome using the Ensembl Genome Browser (http://www.
ensembl.org). This enabled us to determine the number of extra
genes (i.e., genes other than the targeted gene region) spanned
by each unique BAC clone. We report that 75% of the BAC
clones used to derive GENSAT Cre driver lines contain at least
one or more extra gene (Figure 2A), and in the extreme cases
FIGURE 1 | Independent BAC transgenic mouse lines created by
modification of the same original BAC clone exhibit highly
reproducible cell-type specific transgene expression that recapitulates
endogenous gene expression patterns. (A) Sagittal brain section showing
EYFP expression for Chat-EYFP line GH293 mice from the GENSAT project.
(B) Upper, sagittal brain section showing native EYFP fluorescence for
Chat-ChR2(H134R)-EYFP line 6. Lower, high magnification images of
anti-GFP and anti-ChAT co-immunostaining demonstrating excellent
co-localization. (B) Adapted from Zhao et al. (2011). Scale bar: 100 microns.
Note the virtually identical pattern of transgene expression between these
two independent lines shown in (A,B) with strong signal detected in known
cholinergic nuclei including brainstem motor nuclui (facial nucleus and
motor trigeminal nucleus), striatum, olfactory tubercle, and basal forebrain.
Both lines were created by modification of BAC clone RP23-246B12 to
insert the transgene of interest in place of the Chat gene.
up to 14 independent and complete extra genes were spanned
by a single BAC clone (e.g., RP23-368D24 used to create Thbs-
Cre lines SW48-Cre and SW52-Cre; Figure 2B). Only 25% of
BAC clones were entirely devoid of extra genes (12%) or only
contained incomplete portions of gene coding regions (13%).
Notably, many of the analyzed BAC clones used to derive GENSAT
Cre driver lines were also previously implemented for making
EGFP reporter lines.
EXTRA GENES CONTAINED WITHIN BAC CLONES CAN RESULT IN
UNINTENDED GENE OVEREXPRESSION IN BAC TRANSGENIC LINES
The infrequently discussed down side of selecting very large
BAC clones for BAC transgenesis is the potential for overex-
pression of unwanted extra genes and any associated behavioral,
biochemical, or electrophysiological confounds. We previously
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Table 1 | BAC transgenic lines typically have increased gene dosage of one or more extra gene.
Name Species mouse BAC ID Targeted gene Extra genes in BAC clone Citations Unique lines
Adora2a-Cre mouse RP24-238K3 Adora2a Cytsa*, 1110038D17Rik-210*, Upb1 Gong et al., 2007 KG139
Adora2a-EGFP mouse RP24-238K3 Adora2a Cytsa*, 1110038D17Rik-210*, Upb1 Gong et al., 2003 EP141
Adora2a-hM3D mouse RP24-238K3 Adora2a Cytsa*, 1110038D17Rik-210*, Upb1 Farrell et al., 2013 AD6
Chat-ChR2 mouse RP23-246B12 Chat Ogdhl, 1700024G13Rik, Slc18a3, Ercc6ˆ Zhao et al., 2011 Line 5, Line 6
Chat-Cre mouse RP23-246B12 Chat Ogdhl, 1700024G13Rik, Slc18a3, Ercc6ˆ Gong et al., 2007 GM24, GM60, GM53
Chat-Cre rat RP23-246B12 Chat Ogdhl, 1700024G13Rik, Slc18a3, Ercc6ˆ Witten et al., 2011 Line 5
Chat-EGFP mouse RP23-246B12 Chat Ogdhl, 1700024G13Rik, Slc18a3, Ercc6ˆ Gong et al., 2003 GH293
Chat-EGFP mouse RP23-268L19 Chat 1700024G13Rik, Slc18a3, Ercc6ˆ Tallini et al., 2006 Line 2
Chrm4-EGFP mouse RP23-138P5 Chrm4 Ambra1*, Gm9821, Mdk, Dgkz, Creb3l1* Lobo et al., 2006 Y86
Drd1a-Cre mouse RP23-47M2 Drd1a Sfxn1 Gong et al., 2007 FK150, EY262, EY217
Drd1a-EGFP mouse RP23-47M2 Drd1a Sfxn1 Gong et al., 2003 X60
Drd1a-tdTomato mouse RP23-47M2 Drd1a Sfxn1 Ade et al., 2011 Line 6
Drd2-Cre mouse RP23-161H15 Drd2 Ttc12, Ankk1? Gong et al., 2007 ER43, ER44
Drd2-EGFP mouse RP23-161H15 Drd2 Ttc12 Gong et al., 2003 S118
Pvalb-ChR2 mouse RP23-305H12 Pvalb Ift27, Cacng2 Zhao et al., 2011 Line 15
TH-Cre mouse RP23-350E13 TH GM6471, Ascl2 Gong et al., 2007 FI12, FI172
TH-Cre rat RP23-350E13 TH GM6471, Ascl2 Witten et al., 2011 Line 3
Tph2-ChR2 mouse RP23-112F24 Tph2 Tbc1d15* Zhao et al., 2011 Line 5
VGAT-ChR2 mouse RP23-392P11 Viaat (VGAT) Arhgap40, Ralgapb*, Adig, Actr5, Ppp1r16bˆ Zhao et al., 2011 Line 8
Viaat-Cre mouse RP23-392P11 Viaat (VGAT) Arhgap40, Ralgapb*, Adig, Actr5, Ppp1r16bˆ Hagglund et al., 2013 –
Viaat-Cre mouse RP23-392P11 Viaat (VGAT) none reported Chao et al., 2010 Tg2.1
*Partial gene that is missing the first coding exon containing ATG.
ˆ Truncated gene.
FIGURE 2 | Analysis of extra genes spanned by BAC clones of the
GENSAT Cre driver repository. (A) Plot of the percentage of BAC clones
with either zero, partial gene fragments only, or 1 or more extra genes
spanned. (B) Plot of the full distribution of extra gene number for the 139
BAC clones analyzed. Only intact genes that were fully contained within the
BAC clone were counted.
developed a ChAT-ChR2-EYFP BAC transgenic mouse line (line
6) that enables optogenetic control of cholinergic neuron fir-
ing in vitro and in vivo (Ren et al., 2011; Zhao et al., 2011; Ma
and Luo, 2012). The BAC clone that was used to create our
ChR2-EYFP line was the same as the clone used to create inde-
pendent ChAT-Cre mouse and rat lines (Gong et al., 2007; Witten
et al., 2011). This Chat-spanning BAC clone contains the addi-
tional genes Ercc6 (partial), Ogdhl, 1700024G13Rik and Slc18a3
(Figures 3A–C). Importantly, the Slc18a3 gene is nested within
the first intron of the Chat gene and encodes for the vesicular
acetylcholine transporter (VAChT), the overexpression of which
has profound implications for cholinergic function. This pre-
diction was confirmed in a recent study that provided direct
evidence for increased VAChT expression in ChAT-ChR2-EYFP
line 6 mice, and linked this VAChT overexpression to increased
cholinergic tone, enhanced motor endurance, and attention and
memory deficits (Kolisnyk et al., 2013). More specifically, the
authors reported a 20-fold increase in VAChT transcript level in
striatum and a 5-fold increase in VAChT protein level in hip-
pocampus with no significant elevation of ChAT expression in
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FIGURE 3 | Extra genes contained within BAC clones can result in
unintended gene overexpression in BAC transgenic lines. Simplified
diagrams of the Chat-spanning BAC clone RP23-246B12 (A) that was
modified for expression of (B) Cre recombinase (GENSAT BAC ID
BX1191) or (C) ChR2(H134R)-EYFP under the control of the Chat gene
promoter elements. Several extra genes are contained in the BAC clone,
including Ercc6 (partial), Ogdhl, 1700024G13Rik, and Slc18a3. Notably,
Slc18a3 (the gene encoding VAChT) is nested within the first intron of
the Chat gene. (D) Summary of fold changes in VAChT levels (DNA
copies, mRNA, and protein) in brain tissue from Chat-ChR2(H134R)-EYFP
line 6 BAC transgenic mice relative to non-transgenic controls. This
chart is based on data presented in Kolisnyk et al. (2013).
Abbreviations: F, F-factor replicon; CM, chloramphenicol resistance gene.
Both elements are part of the BAC vector.
either region (summarized in Figure 3D). The protein overex-
pression was associated with a 3-fold increase in stimulus-evoked
ACh release in hippocampal slices, consistent with the behavioral
data that VAChT overexpression has important functional con-
sequences (Kolisnyk et al., 2013). Furthermore, striatal VAChT
overexpression and elevated ACh release are associated with
increased severity of psychomotor stimulant-induced repetitive
behaviors in ChAT-ChR2-EYFP line 6 BAC transgenic mice (Jill
R. Crittenden and Ann Graybiel, pers. commun.).
STRATEGY FOR DELETION OF EXTRA GENES BY BAC TRIMMING
The most straightforward approach for eliminating extra genes
contained in BAC clones is to remove segments from either end
of the BAC insert, a method known as BAC trimming or shav-
ing. We implemented a versatile method for BAC trimming in
which small antibiotic selection cassettes are used to replace pre-
cise BAC DNA segments using a recombineering step in E. coli
(Hill et al., 2000; Testa et al., 2003, 2004). The selection cassettes
were PCR amplified using long primers to add ∼50 bp homology
arms to either end, and then used for recombineering in EL250
cells. The homology arms define the exact BAC region that will be
deleted by the insertion of the selection cassette, and the selection
cassette enables subsequent identification of properly modified
BAC clones. In addition, many different selection cassettes can
be utilized for BAC trimming (e.g., ampicillin resistance-bla,
kanamycin resistance-neo, chloramphenicol resistance-cam, blas-
ticidin resistance-bsd, and streptomycin resistance-rpsL), provid-
ing options for sequential rounds of BAC trimming and transgene
targeting using different selection markers. To further generalize
this strategy for deleting fragments from any BAC clone in the
RP23 and RP24 library, in subsequent experiments one of the
homology arms was designed on the end of the BAC vector such
that only the second homology arm needs to be customized for
each unique BAC clone to define the deletion region—the region
containing undesirable extra genes. In addition, we added NotI
and AscI restriction sites adjacent to the unique homology arm
but before the selection cassette. Once the deletion of the BAC
segments was confirmed by restriction digestion and pulsed field
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gel electrophoresis (PFGE) the BAC insert was liberated from
the BAC vector and selection cassette by NotI or AscI digestion
and subjected to further purification. We have used this method
to successfully delete precisely defined BAC DNA segments, as
demonstrated for the Slc6a3-spanning BAC clone RP24-269I17 in
which the extra genes Clptm1l, Tert, Slc6a18, and Slc6a19 located
in the 3′ flanking region of the Slc6a3 (DAT) gene were deleted
by homologous recombination in which an ∼84 kb BAC region
was replaced with a 1 kb ampicillin resistance (AmpR) cassette
(Figures 4A–C). The “trimmed” BAC clone can then be used
for insertion of a transgene cassette in place of the Slc6a3 gene
by standard BAC recombineering using an iTV-based targeting
vector (see Materials and Methods). The successful DAT BAC
trimming was verified by diagnostic restriction digestion with SalI
and PFGE (Figure 4D).
It is worth noting that other methods have been described
for removal of extra genes from BAC clones to produce BAC
transgenic mouse lines. In one study a modified BAC clone was
subjected to restriction digestion and PFGE, and fortuitously, a
fragment could be excised that contained suitably large 5′ and
3′ flanking regions but excluded several extra genes originally
present in the BAC clone (Chao et al., 2010). In another study
a spontaneous deletion was identified in a single clone during the
recombineering steps, and this deletion serendipitously removed
the only extra gene present in the BAC clone (Belforte et al., 2010).
However, the recombineering-based method we have outlined for
FIGURE 4 | BAC recombineering strategies for avoiding expression of
extra genes. (A) Strategy for deletion of extra genes by BAC trimming. A
diagram of the DAT (Slc6a3)-spanning BAC clone RP24-269I17 reveals the
presence of many extra genes including Clptm1l, Tert, Slc6a18 and the
truncated genes Lpcat1 and Slc6a3. (B) The extra genes Clptm1l, Tert,
Slc6a18, and Slc6a19 located in the 3’ flanking region of the DAT gene are
deleted by homologous recombination. The recombination event replaces the
∼84 kb BAC region with a 1 kb ampicillin resistance (AmpR) cassette.
(C) Diagram of the “trimmed” DAT BAC clone that can now be used for
insertion of a transgene cassette in place of the DAT gene by BAC
recombineering. (D) Verification of DAT BAC trimming by diagnostic
restriction digestion with SalI and PFGE. Lane 1 and 2: modified DAT BAC
DNA. Lane 3 and 4: trimmed DAT BAC DNA. Lane 5: MidRange I PFG Marker.
In successfully trimmed BAC clones the 91 kb DNA fragment (blue arrow) is
reduced to 17 kb (red arrow). In addition, a 6 and 4 kb fragment are deleted
but are too small to be visualized on the PFG. (E) Strategy for inactivation of
extra genes by dual targeting. The Drd1a-spanning BAC clone RP23-47M2
contains the extra gene Sfxn1 in the promoter region of the Drd1a gene. In
the dual targeting strategy, two simultaneous homologous recombination
events must occur. The first targeting event is the insertion of the transgene
cassette (including the NEO selection marker) in place of the Drd1a gene.
The second targeting event is the insertion of a triple frame stop mutation
(and SalI restriction site) immediately downstream of the Sfxn1 start codon.
Double recombinant clones are identified by kanamycin resistance. (F)
Verification of Sfxn1 gene inactivation in modified Drd1a BAC DNA by
diagnostic restriction digestion with SalI and PFGE. Lane 1: MidRange I PFG
Marker. Lane 2: 2.5 kb marker. Lane 4: Drd1a BAC DNA (+Sfxn1). Lanes 6–8:
Drd1a BAC DNA following Sfxn1 inactivation. For successfully modified BAC
clones the ∼95 kb DNA fragment (blue arrow) is cleaved into 60 and 35 kb
fragments (red arrows). Note that all other bands remain unaltered.
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BAC trimming affords greater reliability and precision for routine
deletion of extra genes.
INACTIVATION OF POTENTIALLY CONFOUNDING “EXTRA” GENES BY
MINIMAL INSERTION MUTATIONS
Although BAC trimming can be a versatile and powerful method
for deleting both small and large segments of BAC DNA, in some
cases it is not permissible to apply this method for the removal
of extra genes. For example, when an extra gene is located within
the critical 5′ and 3′ flanking regions of the targeted gene, dele-
tion of these flanking regions would likely negatively affect the
pattern of gene expression. Thus, we devised a recombineering
strategy to inactivate the Sfxn1 gene nested within the putative
promoter region of the Drd1a gene by inserting stop codons in all
three reading frames to interrupt the coding region of Sfxn1. In
this manner the inactivation of an extra gene can be carried out
with minimal insertions as small as ∼15 bp, but in our case we
have designed a 29 bp sequence (see Materials and Methods) for
targeted inactivation of Sfxn1 gene in the Drd1a-spanning BAC
RP24-47M2 that further introduces unique restriction sites for
diagnostic purposes (Figure 4E). The targeting vector for gene
inactivation does not contain any selection marker and therefore
must be used in conjunction with a second targeting vector that
does contain a selection marker, in this case either an iTV-based
targeting vector or a BAC trimming cassette.
In order to ensure that the antibiotic selection appropriately
isolates double recombinant clones, the concentrations of the
linearized targeting vectors were carefully proportioned. The lin-
earized Sfxn1 Target and iTV1-D1-ChETA Target DNA were
combined at∼20:1 for the dual targeting step in EL250 cells prop-
agating RP23-47M2 in order to favor a high likelihood of isolating
clones with successful inactivation of Sfxn1. Initial attempts did
not yield correct double recombinant clones, but instead, only the
ChETA cassette with selection marker were found to be inserted
in recovered BAC clones. The results were markedly improved
by using high quality MAXI prep DNA of high concentration,
ensuring the linearization was complete with no uncut plasmid
remaining, and use of LB Lennox media instead of LB Miller in
the recombineering protocol. With these changes the majority
of experiments yielded one or more correct double recombi-
nant BAC clones with insertion of the ChETA expression cassette
downstream of the Drd1a promoter region and inactivation of
Sfxn1 by insertion of the three-frame stop mutation immediately
downstream of the Sfxn1 start codon. The insertion of the inacti-
vation cassette incorporated a new diagnostic SalI restriction site
adjacent to the three-frame stop mutation, and thus, it was feasi-
ble to verify Sfxn1 inactivation at the DNA level by SalI digestion
and PFGE (Figure 4F).
PRESERVED CELL-TYPE SPECIFIC EXPRESSION PATTERNS IN BAC
TRANSGENIC MICE CREATED WITH ADVANCED RECOMBINEERING
STRATEGIES
An important consideration for the BAC trimming and gene
inactivation strategies employed here is whether or not the BAC
DNA manipulations ultimately negatively impact the transgene
expression pattern in transgenic animals. Although these strate-
gies appear highly effective for removal of unwanted genes from
BAC clones, the utility of such manipulations would be greatly
diminished if the cell type-specific expression patterns were not
preserved. To demonstrate faithful expression we created BAC
transgenic mouse lines for expression of the fast kinetic ChR2
variant ChETA under the regulatory elements forAdora2A (A2A),
Drd1a (D1), and Slc6a3 (DAT). The BAC clones were modified
as described using BAC trimming or gene inactivation strategies
such that no unwanted extra genes were present. The modi-
fied BAC clones were used for pronuclear injection to create
BAC transgenic founders. In each case we were able to success-
fully identify a single founder line for A2A-ChETA, D1-ChETA,
and DAT-ChETA with functional transgene expression match-
ing to the respective endogenous expression patterns (Figure 5).
In order to further validate transgene expression in D1-ChETA
mice we crossed these mice to the well characterized D1-EGFP or
D2-EGFP GENSAT BAC transgenic mice. Our analysis revealed a
near perfect overlap of EGFP and tdTomato (proxy for ChETA)
restricted to striatonigral medium spiny neurons (MSNs) in D1-
EGFP/D1-ChETA double transgenicmice (Figures 6A,B). In con-
trast, virtually no overlap in EGFP and tdTomato expression was
observed in the dorsal striatum region of D2-EGFP/D1-ChETA
double transgenic mice indicating exclusion of ChETA expression
from striatopallidal MSNs (Figures 6C,D).
DISCUSSION
We have designed and implemented BAC recombineering strate-
gies for eliminating undesirable extra genes from BAC clones in
order to circumvent confounds due to overexpression of extra
genes in BAC transgenic lines. The BAC recombineering strategies
are simple, efficient, and reproducible and have been imple-
mented to successfully modify numerous mouse BAC clones from
the RP23/RP24 library. Our BAC trimming strategy enables pre-
cisely targeted deletions of undesirable BAC DNA regions, such
as those stretches harboring off-target extra genes. By judicious
selection of BAC clones, in most cases it is feasible to remove all
unwanted extra genes with a single deletion step targeting only
one end (rather than both ends) of the BAC. We have demon-
strated precise deletions of up to 111 kb and spanning as many as
four unique genes in a single recombineering event with no evi-
dence for any upper size limit thus far. Notably, excessive removal
of large expanses of BAC DNA can be detrimental to the intended
transgene expression pattern. Thus, although BAC trimming may
be optimal for a wide variety of applications, it may not be feasi-
ble to fully remove all unwanted portions of BAC DNA for every
BAC clone of interest.
In some BAC clones a gene of interest may occasionally be
found to reside in very close proximity to a separate off-target
gene, as was the case for the Drd1a and Chat spanning BAC
clones in our study. In such cases a simple BAC trimming strategy
is not suitable since deletion of the unwanted extra gene would
also eliminate putative 5′ or 3′ regulatory elements essential for
specifying the unique expression pattern of the targeted gene.
Thus, a gene inactivation strategy was implemented to insert a
three-frame translational stop mutation plus diagnostic restric-
tion site immediately downstream of the initiating methionine
start codon in the unwanted extra gene. The size of the inacti-
vation cassette is intentionally minimal (e.g., lacking antibiotic
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FIGURE 5 | Preserved cell-type specific expression patterns in BAC
transgenic mice created with advanced recombineering strategies.
(A–D) Anti-2A slice staining in brain slices from DAT-ChETA line 3 mice
reveals the distribution of membrane-targeted ChETA protein. Sagittal (A) and
coronal (B) sections showing ChR2 expression in midbrain dopamine
neurons. (C,D) High magnification images of axon terminal labeling in the
dorsal striatum (C) and labeled neurons in the ventral tegmental area (D).
(E,F) Anti-RFP slice staining in brain slices from A2A-ChETA line 13 mice
showing tdTomato expression in striatopallidal medium spiny neurons
(MSNs) in coronal (E) and sagittal (F) sections. Lighter expression can also be
detected in putative cortical astrocytes. (G) Anti-2A slice staining in a sagittal
brain slice from D1-ChETA line 1 mice showing ChETA expression in
striatonigral MSNs. Additional expression is apparent in other brain regions,
particularly the dentate gyrus, layer VI cortex, and olfactory bulb.
(F) Anti-DARPP32 slice staining to label both striatonigral and striatopallidal
MSNs. Scale bars: 1mm in (A,B,E–H) and 100µm in (C,D).
selection cassette) and serves to eliminate functional gene expres-
sion from the unwanted extra gene without additional disruption
to important regulatory elements in the region. The BAC recom-
bineering strategy for gene inactivation requires dual targeting
together with a second targeting cassette incorporating a func-
tional selection marker. This dual targeting strategy allows for
simultaneous insertion of a transgene cassette and inactivation of
an extra gene by selecting for clones that have undergone suc-
cessful homologous recombination at both locations within the
BACDNA sequence—i.e., double recombinant clones. In order to
ensure a high likelihood that the antibiotic selection appropriately
isolates double recombinant clones, the concentrations of each
linearized targeting vector must be carefully proportioned. With
optimization, the dual homologous recombination step was effi-
cient enough to routinely identify multiple successfully targeted
clones in a single attempt.
The overall goal of our efforts was to remove all extra genes
from the selected BAC clones using either or both of these versa-
tile recombineering strategies, leaving only a single targeted gene
with sufficient 5′ and 3′ flanking regions to direct faithful gene
expression in vivo in transgenic mice derived from pronuclear
injection of the modified BAC DNA. In essence, the resultant
modified BACs could be considered as designer “mini BACs”
that retain only the most essential elements from the parent BAC
clone while removing all non-essential portions. In designing
our approaches we have had excellent initial success following a
general guideline of retaining at least 50 kb of 5′ sequence and
15–20 kb of 3′ sequence flanking the targeted gene within BAC
clones; however, the extent of 5′ and 3′ regions required must
be determined empirically on a case-by-case basis. Once a suc-
cessfully modified BAC clone is validated for proper cell-type
specific expression, the same BACmodification strategy or prefer-
ably the same trimmed BAC clone itself can then be re-purposed
for subsequent recombineering and expression of virtually any
other transgene of interest. We provide a list of several BAC clones
that have been modified using these methods and that can be uti-
lized to target transgene expression to defined neuronal subsets
(Table 2).
The approaches we have described for modifying BAC DNA
using recombineering in E. coli build upon and extend the work
of others. In three earlier studies BAC trimming (sometimes
also called BAC shaving) was similarly accomplished by targeted
replacement of a DNA region with a selection marker using
homologous recombination (Hill et al., 2000; Testa et al., 2003,
2004). The end goal of such BAC DNA manipulation strategies
was either to create precise vectors for traditional gene targeting
in mouse embryonic stem cells or to reduce redundant effort in
genome sequencing projects. In contrast, we applied BAC trim-
ming to eliminate extra off-target genes so as to avoid potentially
confounding effects in mice derived from pronuclear BAC DNA
injections.
A substantially different method of retrieving mini BAC frag-
ments was previously described. This method utilized PCR and
gap repair in E. coli to subclone ≤80 kb BAC fragments into the
low copy number pBR322 vector (Lee et al., 2001). However,
the resulting transgene expression patterns were highly variable
and did not fully recapitulate the endogenous gene expression
patterns. This stands in contrast to our results demonstrating
excellent preservation of the intended cell-type specific transgene
expression patterns in transgenic mice derived from BAC DNA
modified using our improved strategies. This difference is likely
due to the strict size limitation for sub-cloning DNA fragments
Frontiers in Behavioral Neuroscience www.frontiersin.org April 2014 | Volume 8 | Article 111 | 9
Ting and Feng BAC transgenic tools for optogenetics
FIGURE 6 | Validation of transgene expression in striatonigral but
not striatopallidal MSNs in D1-ChETA line 1 mice. (A,B) Confocal
images in brain slices from D1-EGFP/Drd1a-ChETA double transgenic
mice. (A) Substantia nigra pars reticulata (SNr) region showing
anti-EGFP (Ai), native tdTomato fluorescence (Aii), and the merged
image (Aiii). (B) Images from the dorsal striatum (DStr) region. (C,D)
Confocal images in brain slices from D2-EGFP/D1-ChETA double
transgenic mice. (C) SNr/VTA boundary showing anti-EGFP (Ci), native
tdTomato fluorescence (Cii), and the merged image (Ciii). (D) Images
from the DStr region.
into pBR322, whereas no practical size limitation is expected with
typical BAC vectors such as pBACe3.6 and pTARBAC1, particu-
larly since BAC DNA is being trimmed rather than retrieved by
gap repair. Thus, the approaches that we have described seem to
be more flexible when selection of considerably larger 5′ or 3′
regions surrounding the target expression cassette are required for
achieving faithful expression in vivo, as is most often the case.
There are now extensive repositories of BAC transgenic mouse
lines available, including over a thousand distinct Cre driver and
EGFP reporter lines produced by the GENSAT project alone. We
analyzed the full collection of BAC clones used for creating the
extensive GENSAT Cre driver repository as a representative data
set and determined that 75% of the BAC clones contain at least
one or more extra genes. Even more surprisingly, one-third of the
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Table 2 | Successfully modified BAC clones using BAC trimming and gene inactivation approaches.
Targeted BAC ID BAC size deletion trimmed deleted genes inactivated genes insertion size (bp)
gene (kb) size (kb) BAC size (kb)
Drd1a RP23-47M2 283.0 – – – Sfxn1ˆ 29 bp
Drd2 RP23-161H15 226.8 77.9 148.9 Ttc12, Ankk1 – –
Adora2a RP24-238K3 186.0 50.8 135.2 1110038D17Rik-210*, Upb1 – –
Slc6a3 (DAT) RP24-269I17 199.7 84.0 115.7 Clptm1l, Tert, Slc6a18, Slc6a19* – –
Pvalb RP24-306A6 140.4 52.4 88.0 Ift27 – –
Viaat (VGAT ) RP24-246L1 177.0 111.0 66.0 Actr5, Ppp1R16b* – –
Chat RP24-256F2 176.2 43.5 132.7 1700024G13Rik, Ercc6* Slc18a3ˆ 29 bp
*Partial gene sequence only.
ˆ Gene inactivation by insertion of a 3-frame triple STOP cassette.
BAC clones contained at least three or more extra genes and 5%
contained at least nine or more extra genes. The most extreme
case was a BAC clone that spanned fourteen different fully intact
extra genes, and this clone was used to create both Cre driver and
EGFP reporter lines (Thbs3-spanning BAC clone RP23-368D24).
Despite the extensive proven utility of numerous GENSAT lines,
it is an unfortunate possibility that many available BAC trans-
genic lines may suffer from confounds of varying degrees due
in part to overexpression of one or more “extra” genes. In some
cases the unintended overexpression of one or more extra genes
in various tissues of transgenic animals may have profound con-
sequences and implications for interpreting experimental results.
In other cases the extra genes may not be expressed at func-
tionally relevant levels or perhaps there may be no measurable
impact despite high level expression (Heiman et al., 2008). In
support of the former, recent experimental evidence has emerged
claiming significant behavioral and functional alterations in sev-
eral commonly used BAC transgenic mouse lines (Ade et al.,
2011; Bagetta et al., 2011; Kramer et al., 2011; Kolisnyk et al.,
2013), thereby raising concerns about some aspects of the find-
ings from the numerous studies that have implemented these lines
to date. Although some aspects of the reported defects have been
disputed or reconciled (Chan et al., 2012; Nelson et al., 2012),
this controversy highlights the need for more rigorous system-
atic characterization of BAC transgenic lines. In the study by
Kolisnyk et al. (2013) it was clearly demonstrated that the mea-
sured behavioral and physiological alterations were the direct
result of high BAC copy number insertion and unintended over-
expression of VAChT in Chat-ChR2(H134R)-EYFP line 6 BAC
transgenic animals (Kolisnyk et al., 2013). Given this finding, fur-
ther detailed investigations are likely to reveal significant impacts
of overexpressed extra genes in many other widely used BAC
transgenic lines. This point underscores the potential benefits
of the improved BAC recombineering strategies we have devel-
oped for removing or inactivating extra genes for the purpose of
creating transgenic tools with fewer potential confounds.
Beyond the limited examples we have cited above, there are
undoubtedly many commonly used BAC transgenic lines for
which behavioral or physiological confounds are likely but have
yet to be directly assessed. As an example, several BAC transgenic
lines have been reported for transgene expression in cholinergic
neurons using identical or highly similar Chat-spanning BAC
clones as the one used in developing the Chat-ChR2(H134R)-
EYFP line 6 mice. These include a Chat-Cre driver line (Gong
et al., 2007), two distinct Chat-EGFP reporter lines (Gong et al.,
2003; Tallini et al., 2006), and a Chat-L10a-EGFP BacTRAP line
(Doyle et al., 2008). Furthermore, a Chat-Cre BAC transgenic rat
was developed by pronuclear injection of the identical Chat-Cre
mouse BAC clone used to create the Chat-Cre mouse line (Witten
et al., 2011). Thus, although no direct assessment of VAChT over-
expression has been reported for these five independent lines,
it is expected that all will have some degree of overexpression
of VAChT (and potentially Ogdhl and 1700024G13Rik) depend-
ing on the BAC transgene copy number for each line. However,
it is worth noting that high BAC copy number insertions as
reported for the ChAT-ChR2(H134R)-EYFP line 6 tend to be far
less common as opposed to low BAC copy number insertions.
In the long-term, we propose that the most effective strat-
egy will be to re-engineer and develop new BAC transgenic lines
using improved BAC recombineering strategies to eliminate non-
essential portions of BAC DNA, including (but not limited to),
methods described in this study, and to deposit validated mini
BACs into an open source repository for widespread use. The
versatile new resources we have developed (e.g., BAC modifi-
cation vectors and successfully modified BAC clones) and the
simple and efficient methods we have demonstrated should facil-
itate progress in this area by providing further options to support
diverse recombineering needs. Furthermore, with advances in
pronuclear injection-based targeted transgenesis (Ohtsuka et al.,
2010; Tasic et al., 2011) and identification of “safe” genomic dock-
ing loci permissible for high level expression, it may soon be
possible to develop BAC transgenic animals that are free of both
confounding extra genes and detrimental positional effects from
random transgene integration. Continued technological innova-
tion will help to ensure an ever-expanding collection of highly
useful BAC transgenic tools that can pave the way to deciphering
the functions of the remarkably diverse cell types in the brain.
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